Evidence map›Paper›PMID 40953954›Full record

ArticleThe Journal of rheumatology2025

Differences in Cause-Specific Mortality in Patients With Rheumatoid Arthritis by Sex and Seropositivity.

Elena K Joerns, Andrea Lopez-Ruiz, Ryan J Lennon, Cynthia S Crowson, Roslin Jose George, Vanessa L Kronzer, John M Davis, Elena Myasoedova

Abstract read
In one paragraph

Article in The Journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elena K JoernsE.K. Joerns, MD, MPH, R.J. George, MBBS, MPH, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; joerns.elena@mayo.edu.ORCID 0000-0001-7089-9152
Andrea Lopez-RuizA. Lopez-Ruiz, BS, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona.ORCID 0009-0004-1339-4827
Ryan J LennonR.J. Lennon, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8366-8422
Cynthia S CrowsonC.S. Crowson, PhD, Elena Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, and Department of Quantitative Health Sciences, Mayo Clinic, Minnesota, Rochester, USA.ORCID 0000-0001-5847-7475
Roslin Jose GeorgeE.K. Joerns, MD, MPH, R.J. George, MBBS, MPH, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0000-2697-3511
Vanessa L KronzerE.K. Joerns, MD, MPH, R.J. George, MBBS, MPH, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7489-3134
John M DavisE.K. Joerns, MD, MPH, R.J. George, MBBS, MPH, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9710-8143
Elena MyasoedovaC.S. Crowson, PhD, Elena Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, and Department of Quantitative Health Sciences, Mayo Clinic, Minnesota, Rochester, USA.ORCID 0000-0003-2006-1436

Funding

HEART DISEASE IN RHEUMATOID ARTHRITISR01AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2000 to 2022
$11.3M
Role of Systemic Inflammation in Cognitive Decline: Rheumatoid Arthritis as a PrototypeR01AG068192 · NIA · MAYO CLINIC ROCHESTER · PI Elena Myasoedova · 2020 to 2026
$4.4M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Population-Based Outcomes Research for Rheumatoid Arthritis: Rural Health DisparitiesR01AR084831 · NIAMS · MAYO CLINIC ROCHESTER · PI Cynthia S Crowson · 2024 to 2026
$2.4M
Temporal associations between systemic inflammation, cardiovascular risk profile and development of Alzheimer’s disease and related dementias in patients with rheumatoid arthritisK24AG078179 · NIA · MAYO CLINIC ROCHESTER · PI Elena Myasoedova · 2022 to 2026
$951k
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR21AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2018 to 2019
$437k
NIAMS NIH HHS R01 AR046849NIAMS NIH HHS R01 AR084831NIA NIH HHS K24 AG078179NIA NIH HHS R01 AG068192NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

objectiveOur aims were to investigate the trends in observed vs expected all-cause mortality and the effects of serostatus and sex on all-cause and cause-specific mortality in individuals with rheumatoid arthritis (RA) in a large community-based longitudinal cohort study.

methodsThis retrospective cohort study evaluated all-cause and cause-specific mortality in RA using a community population-based inception cohort of adult residents of Olmsted County, Minnesota, with incident RA from 1980 to 2019 meeting American College of Rheumatology 1987 criteria, and non-RA residents matched 3:1 to patients with RA by age and sex. Underlying cause of death was obtained from death certificates. Competing risks/cumulative incidence methods were used to compare cause-specific mortality incidence between individuals with and without RA. Cox models estimated the effect of RA on risk of cause-specific mortality, adjusting for sex, age, and calendar year of index. Interactions for RA with sex, age, seropositivity, and calendar year were examined.

resultsThe study included 1337 patients with RA and 4011 non-RA comparators. All-cause mortality was significantly increased in both female and male individuals with RA, specifically in seropositive RA, and declined after the 1980s. The increased risk of death due to respiratory causes in patients with RA was significantly different depending on seropositive vs seronegative status (adjusted hazard ratio 2.26 [95% CI 1.56-3.26] vs 0.52 [95% CI 0.24-1.13], interaction

conclusionSeropositivity in persons with RA associates with a significantly increased risk of death, particularly due to respiratory causes, whereas no increased risk was found in seronegative patients.

Indexed as

Arthritis, RheumatoidAdultAgedCause of DeathFemaleHumansLongitudinal StudiesMaleMiddle AgedMinnesotaRetrospective StudiesSex Factorsanticyclic citrullinated peptidecause of deathmortalityrheumatoid arthritis

Identifiers

PMID40953954
PMCPMC12538505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.